Resource Center

Stories

The IRE Resource Center is a major research library containing more than 23,250 investigative stories — both print and broadcast.

These stories are searchable online or by contacting the Resource Center directly (573-882-3364 or rescntr@ire.org) where a researcher can help you pinpoint what you need.

Browse or search the tipsheet section of our library below. Stories are not available for download but can be easily ordered by contacting the Resource Center:



Search results for "AstraZeneca" ...

  • "Making a Killing"

    A 26-year-old bipolar student enrolled in a drug trial at the University of Minnesota. However, Carl Elliott reveals that the professors who were ran the study knew that the student was probably "not competent to give his consent" because he suffered from "severe psychotic delusions." He was given a powerful antipsychotic and eventually stabbed himself to death. Elliott is "a professor of medical ethics at the University of Minnesota," and believes that the professors who were running the drug study would profit from it and that the student who committed suicide was "coerced" into participating.

    Tags: bipolar; drug trial; antipsychotic; Seroquel; University of Minnesota; AstraZeneca

    By Carl Elliott; Clara Jeffery

    Mother Jones

    2010

  • National Cancer Institute silent after not-so-new data on tamoxifen criticized

    Cancer Times gives an overview of a pharmaceutical firm's ad campaign that urged healthy women to assess their breast-cancer risks. Author reports on how the National Cancer Institute "deliberately concealed risk information during the Food and Drug Administration approval process."

    Tags: AstraZeneca; FDA; breast cancer

    By Mary Ann Swissler

    CAncer Times

    1999

  • Cancer Season: National Breast Cancer Awareness Month

    Cancer Times focuses on the negative opinion most activist groups have about National Breast Cancer Awareness Month. Critics charge the month is a PR gimmick and question AstraZeneca's sponsorship of the month. They say AstraZeneca advises early detection and its drug tamoxifen for "high-risk" women.

    Tags: Breast cancer; mammograms; AstraZeneca; NBCAM; Komen Foundation Race for the Cure

    By Mary Ann Swissler

    CAncer Times

    1999